Clinical Trials Logo

Clinical Trial Summary

Mystical experience is described as an experience that is unique to everyone, potentially transformative and leaving a mark for many years or even a lifetime. It is characterized by: a loss of self/ego, being with the whole/nature/universe, transcendence, a loss of spatio-temporal reference points, ineffability, peace and joy, a sacred character, and a noetic quality. The mystical experience is one that occurs in the context of non-ordinary states of consciousness such as meditation and the consumption of so-called psychedelic drugs, for example. It would seem, in fact, to correspond to the transformative mechanism of the psychedelic experience. The goal ofthis study is to investigate the possibility of a mystical experience through hypnosis.


Clinical Trial Description

Anyone interested in taking part in the study will be contacted by telephone or e-mail and offered a face-to-face appointment to carry out the screening (T0). During the appointment, screening (cf. inclusion criteria) will be carried out, socio-demographic data (age, sex, education, nationality, history of hypnosis practice, etc.) and randomization will also take place at this time. At this time, the investigators will assess psychological flexibility and psychologigal well-being, and participants will do a cognitive flexibility task (T1). If people meet the inclusion criteria, the investigators will schedule an appointment for a session to take place roughly a week later. During this session, the investigators will start by reviewing beliefs about hypnosis, assessing participants' expectations of the study, their absorption and dissociation trait, their positive and negative affects and their anxiety. Next, the investigators will perform a 15-minute resting electroencephalographic (EEG) recording. We will then administer the Elkins Hypnotizability Scale. A 30-minute break will be taken. Next, the investigators willperform a hypnotic induction followed by a mystical experience suggestion for the experimental group. The control group will simply receive a reading of the mystical experience suggestion without hypnosis. The rest of the procedure is the same for both groups. EEG activity will be recorded during the mystical experience suggestion (± 15 minutes) in hypnosis and outside hypnosis (ordinary state of consciousness). Directly afterwards, participants will be asked to orally explain their subjective experience during the suggestion of mystical experience. Then the investigators will assess the positive and negative affect in addition to these outcomes: the mystical experience, the ego dissolution, the psychological flexibility, the cognitive flexibility, the altered state of consciousness, the near-death experience, alterness, absorption state, dissociation state, time perception (T2). Three months after receiving the experimental session, participants will be seen again for a follow-up session (T3). During this session, we will ask: "Since the experimental session, have you observed any changes in your behaviors, emotions and beliefs? If so, can you tell us about them?". The investigators will assess the positive and negative affects and psychological well-being. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06017388
Study type Interventional
Source University of Liege
Contact Aminata Bicego
Phone +3243663499
Email abicego@uliege.be
Status Recruiting
Phase N/A
Start date September 1, 2023
Completion date January 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1